The Decline of Pharmaceutical Innovation in Europe
The first keynote speaker Georgette Lalis, Head of DG Enterprise and Industry for the European Commission, began her presentation "The Decline of Pharmaceutical Innovation in Europe" by acknowledging, "Innovation is the life blood of the pharmaceutical industry." She added that regulators must be equally innovative, playing a key role in the growth of R&D development in Europe, noting that Europe is facing massive health threats and the health system is under distress.
The first keynote speaker Georgette Lalis, Head of DG Enterprise and Industry for the European Commission, began her presentation "The Decline of Pharmaceutical Innovation in Europe" by acknowledging, "Innovation is the life blood of the pharmaceutical industry." She added that regulators must be equally innovative and play a key role in the growth of R&D development in Europe, noting that Europe is facing massive health threats and has a health system that is under distress.
Lalis suggested that Europe needs to inject a new impetus and not increase barriers-this will help develop a firm foundation for innovation. And although a great deal has been achieved (such as successful orphan regulation, an increase in the number of new medicines and pediatric medications, and developing legislation for tissue engineering and cell therapy), what has been done so far is still not enough. Lalis added that the Commission will propose a series of measures to remove bureaucratic hurdles and that there needs to be a refocus on non-legislative areas, such as improving information to patients, assessing cost effectiveness of drugs, and looking for alternative approaches to pricing. "Innovation is not new to Europe," she concluded.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
